With the globalization of pharmaceutical research and development, more and more clinical trials need to take into account three major markets including US, Europe and China. Under such circumstance, the international multi-center clinical trial has become an industrial trend of new drug research and development. However, the international multi-center R&D of new drugs is facing a special challenge: due to policy restrictions in various countries, it is almost impossible for samples of subjects to be exported to labs in other countries for analysis.

In order to adapt to the development trend of international multi-center clinical trial cooperation and meet the needs of global customers to a better extent, a strategic partnership has been officially established between Teddy Lab and the MLM medical lab with a long history in Europe, both of whom will carry out extensive cooperation in the field of international multi-center clinical trial central labs to serve for international multi-center clinical trials together and to provide one-stop central lab service.

Headquarter of MLM medical lab

Located in Germany with an area of about 2600 m²and with GLP certification, the headquarter ofMLM medical lab is accredited by CLIA, CAP and DIN EN ISO15189, and provides treatment for diabetes, tumor, infectious diseases, skin diseases, cardiovascular diseases, nervous system and immune system diseases. So far, it has provided services for more than 40 countries in the world in more than 140 Phase I-IV international clinical researches. MLM has over 70 employees, among which more than 30% have doctor’s degree or above.

MLM medical lab

As an active international medical lab, MLM is committed to providing central lab service for clinical trials, just like Teddy Lab. The two parties have a lot in common: both are CAP certified and of the experience in international multi-center clinical trials. Both provide one-stop whole-process central lab services for clinical trials ranging from collection package management to report analysis, and provide more elaborate and valuable reports for clinical trials through comprehensive and rigorous detection service and data management service.

MLM team’s visit in Teddy Lab

With regard to this strategic cooperation, Xu Yi, General Manager of Teddy Lab remarked that “the quality system and management capability of MLM central lab are admirable. We’ve been looking forward to cooperating with MLM medical lab. Since joining ICH in 2017, Teddy Lab has kept exploring the global clinical research market and strengthening our ties with European customers, seeking to be the pioneer of central lab services for international multi-center clinical trials.”

Dr. Stephan Wnendt, President of MLM medical lab, commented on Teddy Lab that, “during this visit in Teddy Lab, we’re deeply impressed by its professional equipment and experienced and professional employees. As a central lab providing services for clinical trials, Teddy Pharceutical bears the business philosophy and strategies almost matching those of MLM perfectly.”

International cooperation of  Teddy Lab

In recent years, Teddy Lab has continuously improved its capability to serve international multi-center clinical trials by means of strategic cooperation with a number of CRO central labs including BARC, ICON and Hematogenix. Through a strict technology transfer system, Teddy Lab has successfully transferred leading technologies of many international CRO central labs or has independently developed and verified different biomarkers, completing the transformation from business process to technical platform, and has undertook and completed perfectly the central lab detection projects for clinical trials of many customers at home and abroad including Johnson & Johnson, Pfizer, Hanson, etc.

Teddy Lab

The cooperation with MLM will open up a new chapter of Teddy Lab in strategic cooperation with international central labs, and help Teddy Lab realize more diversified and international detection services and keep in line with the international quality standards and management systems for R&D to promote international recognition of China’s clinical trial data.